PMID- 36084722
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20220926
IS  - 1872-7786 (Electronic)
IS  - 0009-2797 (Linking)
VI  - 366
DP  - 2022 Oct 1
TI  - Anemoside B4 protects against IgE-dependent allergic responses by suppressing the 
      PLC/IP3 and JAK/STAT3 pathways.
PG  - 110153
LID - S0009-2797(22)00358-1 [pii]
LID - 10.1016/j.cbi.2022.110153 [doi]
AB  - Anemoside B4 (AB4) is a natural triterpenoid abundant in the roots of Pulsatilla 
      chinensis. Although various biological activities have been widely attributed to 
      AB4, few studies have focused on its antiallergic effects. In this study the 
      inhibitory effects of AB4 on immunoglobulin E (IgE)-mediated allergic responses 
      were investigated, both in vitro and in vivo, and the mechanism of its effects. 
      IgE-mediated passive cutaneous anaphylaxis was used to elucidate the antiallergic 
      effects of AB4 in vivo. The degranulation assay, calcium imaging, and cytokine 
      and chemokine release in the laboratory of allergic disease 2 (LAD2) cell line 
      were used to evaluate the antiallergic effect of AB4 in vitro. Pathological 
      staining was performed to analyze angiectasis. Western blot analysis was 
      performed to investigate the downstream signaling pathways. AB4 dose-dependently 
      attenuated ovalbumin/IgE-induced paw swelling in mice, and reduced the serum 
      concentrations of tumor necrosis factor-alpha and C-C motif chemokine 2. In 
      addition, AB4 suppressed IgE-mediated LAD2 cell degranulation, calcium influx, 
      and PLC/IP3 and JAK/STAT3 phosphorylation. Our results suggest that AB4 inhibits 
      allergic reactions through the PLC/IP3 and JAK/STAT3 pathways.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Chang, Yu
AU  - Chang Y
AD  - Department of Clinical Pharmacy, Honghui Hospital, Xi'an Jiaotong University, 
      Xi'an, Shaanxi Province, China.
FAU - Fan, Ting
AU  - Fan T
AD  - Department of Clinical Pharmacy, Honghui Hospital, Xi'an Jiaotong University, 
      Xi'an, Shaanxi Province, China.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Clinical Pharmacy, Honghui Hospital, Xi'an Jiaotong University, 
      Xi'an, Shaanxi Province, China. Electronic address: huangjing87206@126.com.
LA  - eng
PT  - Journal Article
DEP - 20220906
PL  - Ireland
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Cytokines)
RN  - 0 (Saponins)
RN  - 0 (Triterpenes)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (anemoside B4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - SY7Q814VUP (Calcium)
RN  - Congenital disorder of glycosylation, type 2C
SB  - IM
MH  - *Anaphylaxis
MH  - Animals
MH  - *Anti-Allergic Agents/pharmacology/therapeutic use
MH  - Calcium/metabolism
MH  - Cell Degranulation
MH  - Congenital Disorders of Glycosylation
MH  - Cytokines/metabolism
MH  - *Hypersensitivity/drug therapy/pathology
MH  - Immunoglobulin E/metabolism
MH  - Mast Cells
MH  - Mice
MH  - Ovalbumin/pharmacology
MH  - Passive Cutaneous Anaphylaxis
MH  - Saponins
MH  - *Triterpenes/pharmacology
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Allergy
OT  - Anemoside B4
OT  - JAK/STAT3
OT  - Mast cell
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that may appear to 
      influence the work reported in this paper.
EDAT- 2022/09/10 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/09/09 19:23
PHST- 2022/04/05 00:00 [received]
PHST- 2022/08/16 00:00 [revised]
PHST- 2022/09/01 00:00 [accepted]
PHST- 2022/09/10 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/09/09 19:23 [entrez]
AID - S0009-2797(22)00358-1 [pii]
AID - 10.1016/j.cbi.2022.110153 [doi]
PST - ppublish
SO  - Chem Biol Interact. 2022 Oct 1;366:110153. doi: 10.1016/j.cbi.2022.110153. Epub 
      2022 Sep 6.